期刊文献+

CD36在免疫代谢中的作用

The role of CD36 in immunometabolism
暂未订购
导出
摘要 CD36作为一种多功能受体,可识别脂肪酸、氧化低密度脂蛋白、晚期氧化终产物及凋亡细胞等配体,参与脂质摄取、免疫识别与调节、炎症反应、血管生成、细胞黏附及凋亡等多个病理生理过程。CD36的表达受转录和翻译后修饰等多个环节的调控。在巨噬细胞、单核细胞、树突状细胞、T细胞和B细胞等细胞类型中,CD36作为免疫信号传导与脂肪酸代谢转运的双重受体,发挥关键作用。由于代谢性疾病与免疫失调之间联系紧密,融合细胞代谢与免疫学的免疫代谢研究逐渐兴起。CD36因其在不同免疫细胞和非免疫细胞中呈现的多重功能,成为连接免疫与代谢的纽带,对糖尿病肾病、代谢功能障碍相关脂肪性肝病、动脉粥样硬化和恶性肿瘤等多种疾病的免疫代谢状态产生显著影响。 CD36 is a multifunctional receptor that recognizes ligands such as fatty acids,oxidized low-density lipoprotein,advanced oxidation end products,and apoptotic cells.It plays a role in lipid uptake,immune recognition and regulation,inflammatory responses,angiogenesis,cell adhesion,and apoptosis.The expression and intracellular localization of CD36 are regulated by various ligands through transcriptional and post-translational modifications.CD36 functions as a critical receptor for immune signaling,fatty acid metabolism,and transport in diverse cells,including macrophages,monocytes,dendritic cells,T cells,and B cells.The close association between metabolic diseases and immune dysregulation has led to the development of immunometabolism,a research field that integrates cellular metabolism and immunology.Due to its multifaceted roles in different immune and non-immune cells,CD36 serves as a bridge connecting immunity and metabolism,significantly influencing the immunometabolic status in various diseases,such as diabetic nephropathy,metabolic dysfunction-associated steatotic liver disease,atherosclerosis,and cancer.
作者 陈晶蕾(综述) 鲍浩 刘志红(审校) CHEN Jinglei;BAO Hao;LIU Zhihong(National Clinical Research Center for Kidney Diseases,Jinling Hospital,Affiliated Hospital of Medical School,Nanjing University,Nanjing 210016,China)
出处 《肾脏病与透析肾移植杂志》 2025年第6期570-574,共5页 Chinese Journal of Nephrology,Dialysis & Transplantation
基金 江苏省卫生健康委员会医学科研重点项目(K2023003) 南京大学医学院教学改革课题(NDY2025004)。
关键词 CD36 免疫细胞 免疫代谢 CD36 immune cells immunometabolism
  • 相关文献

参考文献1

二级参考文献34

  • 1Hirano T. Abnormal lipoprotein metabolism in diabetic nephropathy. Clin Exp Nephrol,2014,18(2) :206-209.
  • 2Ballantyne CM, Olsson AG, Cook TJ, et al. Influence of low high- density lipoprotein cholesterol and elevated triglyceride on coronary heart disease events and response to simvastatin therapy in 4S. Circulation,2001,104(25) :3046-3051.
  • 3Bays HE, Jones PH, Brown WV, et al. National lipid association annual summary of clinical lipidology 2015.J Clin Lipidol, 2014,8 ( 6 Suppl) : S1-S36.
  • 4Barylski M, Nikfar S, Mikhailidis DP, et al. Statins decrease all-cause mortality only in CKD patients not requiring dialysis therapy--a meta- analysis of 11 randomized controlled trials involving 21, 295 participants.Pharmacol Res ,2013,72:35-44.
  • 5Ting RD, Keech AC, Drury PL, et al. Benefits and safety of long-term fenofibrate therapy in people with type 2 diabetes and renal impairment:the FIELD Study.Diabetes Care,2012,35(2) :218-225.
  • 6Appel GB, Radhakrishnan J, Avram MM, et al. Analysis of metabolic parameters as predictors of risk in the RENAAL study.Diabetes Care, 2003,26( 5 ) : 1402-1407.
  • 7Sacks FM,Hermans MP,Fioretto P, et al.Association between plasma triglycerides and high-density lipoprotein cholesterol and microvascular kidney disease and retinopathy in type 2 diabetes mellitus : a global case-control study in 13 countries.Circulation, 2014, 129(9) :999-1008.
  • 8Turner RC, Millns H, Nell HA, et al. Risk factors for coronary artery disease in non-insulin dependent diabetes mellitus:United Kingdom Prospective Diabetes Study ( UKPDS : 23 ). BMJ, 1998,316 ( 7134 ) : 823-828.
  • 9Katsuki S, Matoba T, Nakashiro S, et al. Nanoparticle-mediated delivery of pitavastatin inhibits atherosclerotic plaque destabilizationf rupture in mice by regulating the recruitment of inflammatory monocytes. Circulation ,2014,129(8) :896-906.
  • 10Reidy K, Kang HM, Hostetter T, et al. Molecular mechanisms of diabetic kidney disease.J Clin Invest,2014,124(6) :2333-2340.

共引文献4

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部